Application of Watson for Oncology in Hepatocellular Carcinoma Surgery

Zhujiang Hospital150 enrolled

Overview

The aim of this study was to evaluate the surgical decisions of Watson artificial intelligence in patients with hepatocellular carcinoma.

Hepatectomy is an effective treatment for patients with hepatocellular carcinoma, but liver failure after hepatectomy may lead to increased postoperative mortality. Therefore, it is very important to make preoperative surgical decisions, evaluate the safety of the operation and identify which patients are likely to suffer from liver failure. The artificial intelligence platform developed by IBM Watson for Watson tumor treatment decisions can provide treatment decisions and corresponding theoretical basis to guide surgical decisions based on the key clinical data of liver cancer patients.

Study Type

OBSERVATIONAL

Enrollment

150

Conditions

Liver Resection

Interventions

Watson on oncology surgery decision evaluationOTHER

Watson on oncology surgery decision evaluation. The system acquires and evaluates a large amount of structured and unstructured data from previous medical records through machine learning and natural language processing, and USES algorithms to select treatment options as the best choice for a particular patient.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. 18 years≤ Age ≤80 years 2. Compling with the diagnosis criteria of complex hepatic carcinoma. 3. Primary hepatic carcinoma without intrahepatic or extrahepatic extensive cancer metastasis, the metastatic hepatic carcinoma whose primary focal has been controlled 4. Preoperative liver function is Child - Pugh grade A or B. 5. The patients are volunteered for the study. Exclusion Criteria: 1. Patients with mental illness. 2. Patients can't tolerate the operation owe to a variety of basic diseases (such as severe cardiopulmonary insufficiency, renal insufficiency, cachexia and blood system diseases, etc.) 3. The patients refused to take part in the study. 4. There are other co-existed malignant tumors. 5. Benign liver diseases

Locations (1)

Zhujiang Hospital of Southern Medical University

Guangzhou, Guangdong, China

Outcomes

Primary Outcomes

Operative outcomes

Operative outcomes such as operative time, estimated blood loss and blood transfusion were recorded.

Time frame: intraoperative

Secondary Outcomes

Postoperative survival

Survival after hepatectomy

Time frame: 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.